Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term outcomes after edoxaban versus warfarin for acute venous thromboembolism
NL-OMON42861Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of edoxaban, warfarin and heparin in deep vein thrombosis (DVT), pulmonary embolism (PE) and venous thromboembolism (VTE) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Cumulative incidence of post-thrombotic syndrome and Pulmonary embolism-related quality of life. Started Apr 2017; status: active, not recruiting.
02
Drugs
edoxabanwarfarinheparin
03
Conditions
deep vein thrombosis (DVT)pulmonary embolism (PE)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON42861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42861.